SAB Bio Q3 Loss Widens to $22.3M as R&D Spend Doubles; $205.3M Cash Covers One Year
SABS sits 29% above its 52-week low of $2.44 on elevated volume (1.9× avg).
Summary
SAB Bio posted a $22.3 million Q3 2026 net loss as R&D spending doubled to $18.1 million on the SAB-142 Phase 2b trial, while $205.3 million in cash and investments covers at least a year of operations. Legacy warrants expired unexercised and 1,049,194 earnout shares returned to treasury.
Key Events · Earnings and Guidance · SABS
-
Q3 Loss Widens on Trial Ramp
Net loss of $22.3 million for the three months ended September 30, 2026, versus net income of $45.4 million a year earlier, which had been driven by a $62.0 million non-cash warrant fair-value gain.
-
R&D and G&A Spending Double
Research and development expense rose 101.5% to $18.1 million and general and administrative expense rose 110.9% to $7.8 million, driven by clinical trial costs and headcount for the SAFEGUARD study.
-
Cash Runway of At Least One Year
Cash, cash equivalents and short-term and long-term investments totaled $205.3 million at September 30, 2026; management states existing resources cover operating cash needs for at least one year.
-
Warrants Expire, Earnout Shares Returned
The 575,000 Public Warrants and 20,860 Private Placement Warrants expired unexercised on October 22, 2026 and were delisted from Nasdaq, and 1,049,194 Earnout Shares were returned to the Company as treasury shares after the five-year earnout period ended without hitting its price thresholds.
Analysis · SABS · Life Sciences
The headline swing from a $45.4 million profit a year ago to a $22.3 million loss this quarter is misleading: last year's profit was an accounting artifact, a $62.0 million non-cash gain on warrant remeasurement, not operations. What matters is spending. R&D rose 101.5% to $18.1 million and G&A rose 110.9% to $7.8 million as the company ramps the registrational Phase 2b SAFEGUARD trial of SAB-142. Against that burn, $205.3 million in cash and investments, plus management's statement that resources cover at least one year of operating needs, removes near-term financing risk. The warrant overhang also shrank: the public and private placement warrants expired unexercised on October 22, 2026 and were delisted from Nasdaq, and 1,049,194 earnout shares were returned to treasury after the five-year earnout period lapsed without hitting its price thresholds.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SABS was trading at $3.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $289.3M. The 52-week trading range was $2.44 to $5.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.